Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: A comparison focusing on HBeAg seroconversion

Liver International

Volumn 30, Issue 4, 2010, Pages 512-520

  Lau, George K K ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

HBeAg seroconversion; Interferon; Nucleoside analog; Telbivudine

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; CYTOKINE; ENTECAVIR; GAMMA INTERFERON; HEPATITIS B(E) ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; PROGRAMMED DEATH 1 RECEPTOR; TELBIVUDINE; TENOFOVIR; TUMOR NECROSIS FACTOR ALPHA;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOMODULATION; LONG TERM CARE; MURINE HEPATITIS CORONAVIRUS; NONHUMAN; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SEROCONVERSION; SURVIVAL RATE; TH1 CELL; TREATMENT DURATION; VIRUS LOAD;

ADENINE; ADJUVANTS, IMMUNOLOGIC; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; PHOSPHONIC ACIDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEROLOGIC TESTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77950615937     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.02198.x     Document Type: Review

References (75)

1. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008, 48:335-52.
2. Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int 2009, 29:100-7.
3. Lau GK, Piratvisuth T. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005, 352:2682-95. for the Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group
4. van Zonneveld M, Zondervan PE. Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine. Liver Int 2006, 26:399-405. for the HBV 99-01 Study Group
5. Chang TT, Gish RG. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006, 354:1001-10. for the BEHoLD AI463022 Study Group
6. Lai CL, Gane E. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007, 357:2576-88. for the GLOBE Study Group
7. Marcellin P, Heathcote EJ, Buti M. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008, 359:2442-55.
8. Hsu YS, Chien RN, Yeh CT. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002, 35:1522-7.
9. Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med 2004, 116:829-34.
10. Hui CK, Leung N, Shek TW. Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients. Hepatology 2007, 46:690-8.
11. Yang HI, Lu SN. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002, 347:168-74. for the Taiwan Community-Based Cancer Screening Project Group
12. Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007, 45:1187-92.
13. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007, 45:507-39.
14. Liaw YF, Leung N, Kao JH. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008, 2:263-83.
15. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009, 50:227-42. European Association for the Study of the Liver
16. Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1997, 26:1338-42.
17. Di Bisceglie AM, Waggoner JG, Hoofnagle JH. Hepatitis B virus deoxyribonucleic acid in liver of chronic carriers: correlation with serum markers and changes associated with loss of hepatitis B e antigen after antiviral therapy. Gastroenterology 1987, 93:1236-41.
18. van Nunen AB, Hansen BE, Suh DJ. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003, 52:420-4.
19. Fried MW, Piratvisuth T, Lau GK. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008, 47:428-34.
20. Gish RG, Lok AS, Chang TT. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007, 133:1437-44.
21. Liaw YF, Gane E, Leung N. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009, 136:486-95.
22. Lin SM, Yu ML, Lee CM. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007, 46:45-52.
23. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999, 29:971-5.
24. van Zonneveld M, Honkoop P, Hansen BE. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004, 39:804-10.
25. Ni YH, Chang MH, Chen PJ. Viremia profiles in children with chronic hepatitis B virus infection and spontaneous e antigen seroconversion. Gastroenterology 2007, 132:2340-5.
26. Chu CM, Liaw YF. Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion. J Viral Hepat 2007, 14:147-52.
27. Liu CJ, Chen PJ, Lai MY. Viral factors correlate with hepatitis B e antigen seroconversion in patients with chronic hepatitis B. Liver Int 2006, 26:949-55.
28. Chu CM, Liaw YF. Spontaneous relapse of hepatitis in inactive HBsAg carriers. Hepatol Int 2007, 1:311-5.
29. Niederau C, Heintges T, Lange S. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996, 334:1422-7.
30. Ahn SH, Park YN, Park JY. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol 2005, 42:188-94.
31. Arase Y, Ikeda K, Suzuki F. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med 2006, 119:e9-16.
32. Yuen MF, Wong DK, Yuan HJ, Sum SM, Lai CL. HBsAg seroclearance in Chinese patients receiving lamivudine therapy for chronic hepatitis B virus infection. J Clin Microbiol 2004, 42:4882-4.
33. Coffin CS, Lee SS. Treatment of HbeAg-positive patients with nucleos/tide analogues. Liver Int 2009, 29:116-24.
34. Janssen HL, van Zonneveld M, Senturk H. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005, 365:123-9.
35. Lau GK, Piratvisuth T, Thongsawat S. Durability of response to peginterferon alfa-2a (40 KD) (PEGASYS) in Asian patients with HBeAg-positive chronic hepatitis B: 12 month follow-up data from a large, randomized study (abstract no. 49). Presented at the 2006 Shanghai-Hong Kong International Liver Congress, 25-28 March 2006, Shanghai, China
36. Piratvisuth T, Lau G, Chao YC. Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatol Int 2008, 2:102-10.
37. Janssen HLA. Peg-interferon for chronic hepatitis B. Presented at the 13th International Symposium on Viral Hepatitis and Liver Disease (ISVHLD), 20-24 May 2009, Washington, DC
38. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008, 49:634-51.
39. Cooksley WG, Piratvisuth T, Lee SD. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003, 10:298-305.
40. Erhardt A, Blondin D, Hauck K. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 2005, 54:1009-13.
41. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000, 33:998-1002.
42. Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 2002, 36:1425-30.
43. Zhao H, Kurbanov F, Wan MB. Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. Clin Infect Dis 2007, 44:541-8.
44. Hou J, Yin YK, Xu D. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology 2008, 47:447-54.
45. Marcellin P, Chang TT. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003, 348:808-16. for the Adefovir Dipivoxil 437 Study Group
46. Ren FY, Piao DM, Piao XX. A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B. World J Gastroenterol 2007, 13:4264-7.
47. Yao GB, Zhu M, Wang YM. A double-blind, double-dummy, randomized, controlled study of entecavir versus lamivudine for treatment of chronic hepatitis B [Chinese]. Zhonghua Nei Ke Za Zhi 2006, 45:891-5.
48. Leung N, Peng CY, Hann HW. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology 2009, 49:72-9.
49. Dienstag JL, Schiff ER, Wright TL. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999, 341:1256-63.
50. Chan HL, Heathcote EJ, Marcellin P. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007, 147:745-54.
51. Yao G, Chen C-W, Lu W-L. Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naïve Chinese patients with chronic hepatitis B: a randomized, multicenter study. Hepatol Int 2008, 2:486-93.
52. Leung NW, Peng CY, Sollano J. Entecavir (ETV) results in higher HBV DNA reduction versus adefovir (ADV) in antiviral-naïve HBeAg(+) adults with high HBV DNA: week 96 results (E.A.R.L.Y Study) (abstract no. 998). J Hepatol 2008, 48((Suppl.)):S373-4.
53. Yao GB, Xu DZ, Ren H. Three years of continuous treatment with entecavir results in high proportions of Chinese nucleoside-naïve patients with undetectable HBV DNA: results from studies ETV-023 and -050 (abstract no. 714). J Hepatol 2008, 48((Suppl.)):S266-7.
54. Chang TT, Yoonn SK, Lai CL. Five year of continuous entecavir (ETV) for nucleoside naive HbeAg (+) chronic hepatitis B (CHB): results from study ETV-901 (abstract no. PE115). Hepatol Int 2009, 3((Suppl.)):86.
55. Heathcote JE, Gane E, deMan R. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-positive patients with chronic hepatitis B (study 103) (abstract no. 158). Hepatology 2008, 48((Suppl.)):376A.
56. Heathcote EJ, Gane E, deMan RA. Three years of tenofovir disoproxil (TDF) treatment in HBeAg-positive patients (HBeAg+) with chronic hepatitis B (study 103): preliminary analysis (abstract no. 483). Hepatology 2009, 50((Suppl.)):533A.
57. Zeuzem S, Gane E, Liaw YK. Baseline characteristics and early on-treatment response predict the outcomes of 2 years telbivudine treatment of chronic hepatitis B. J Hepatol 2009, 51:11-20.
58. Hou J, Jia J, Yin YK. Phase III comparative trial of telbivudine vs lamivudine in Chinese patients: two-year results. Hepatol Int 2007, 1:13.
59. Jia JD, Hou JL, Yin YK. Prolonged efficacy and safety of 3 years of continuous telbivudine treatment in Chinese chronic hepatitis B. Hepatol Int 2009, 3:43.
60. Evans A, Riva A, Cooksley H. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: impact of hepatitis B e-antigen seroconversion. Hepatology 2008, 48:759-69.
61. Wu Z, Yan W, Guo W. Telbivudine preserves Th1 cytokine and inhibits Th2 cytokine production in MHV-3 induced viral hepatitis model (abstract no. 945). Hepatology 2008, 48((Suppl.)):731A.
62. Chisari FV, Ferrari C. Hepatitis B virus immunopathology. Springer Semin Immunopathol 1995, 17:261-81.
63. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005, 5:215-29.
64. Peng G, Li S, Wu W. PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol 2008, 45:963-70.
65. Lau GKK. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon? Liver Int 2009, 29:125-9.
66. Lok AS, Lai CL, Wu PC, Leung EK, Lam TS. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987, 92:1839-43.
67. Liaw YF, Leung NWY. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000, 119:172-80. for the Asian Hepatitis Lamivudine Study Group
68. Yuan HJ, Ka-Ho Wong D, Doutreloigne J. Precore and core promoter mutations at the time of HBeAg seroclearance in Chinese patients with chronic hepatitis B. J Infect 2007, 54:497-503.
69. Chu CM. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 2000, 15((Suppl.)):E25-30.
70. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000, 32:803-6.
71. Dienstag JL, Cianciara J, Karayalcin S. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003, 37:748-55.
72. Lee HC, Suh DJ, Ryu SH. Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion. Gut 2003, 52:1779-83.
73. Lee KM, Cho SW, Kim SW. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepat 2002, 9:208-12.
74. Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003, 38:1267-73.
75. Poynard T, Hou JL, Chutaputti A, Manns M, Naoumov N. Sustained durability of HBeAg seroconversion in chronic hepatitis B patients after treatment with telbivudine (abstract no. 706). J Hepatol 2008, 48((Suppl.)):S263-4.